11月1日,药品分销商卡地纳健康公司盘中股价大涨6.91%,报111.04美元,引发市场广泛关注。公司上调了2025财年每股收益预期,从之前的7.55-7.70美元上调至7.75-7.90美元,超出分析师预期。
数据显示,卡地纳健康第一季度每股收益为1.88美元,高于分析师平均预期的1.62美元。公司表示,业绩向好主要受益于对昂贵的特药和品牌药的强劲需求,推动了制药部门销售增长。作为公司收入的主要来源,制药部门分销品牌药、仿制药、特药以及非处方药等。
随着公司加大在特药领域的布局,其在复杂疾病治疗药物分销方面的竞争力有望进一步提高。卡地纳健康此前以11.2亿美元收购了社区癌症中心运营商Integrated Oncology Network,进军癌症治疗领域。分析人士表示,投资者对公司在特药领域的增长前景较为乐观,支撑了当日股价的大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.